123 related articles for article (PubMed ID: 24329188)
1. Prediction of optimal warfarin maintenance dose using advanced artificial neural networks.
Grossi E; Podda GM; Pugliano M; Gabba S; Verri A; Carpani G; Buscema M; Casazza G; Cattaneo M
Pharmacogenomics; 2014 Jan; 15(1):29-37. PubMed ID: 24329188
[TBL] [Abstract][Full Text] [Related]
2. Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients.
Ye C; Jin H; Zhang R; Sun Y; Wang Z; Sun W; Sun W; Peng Q; Liu R; Huang Y
J Int Med Res; 2014 Feb; 42(1):67-76. PubMed ID: 24287930
[TBL] [Abstract][Full Text] [Related]
3. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
[TBL] [Abstract][Full Text] [Related]
4. Impact of genetic and clinical factors on dose requirements and quality of anticoagulation therapy in Polish patients receiving acenocoumarol: dosing calculation algorithm.
Wolkanin-Bartnik J; Pogorzelska H; Szperl M; Bartnik A; Koziarek J; Bilinska ZT
Pharmacogenet Genomics; 2013 Nov; 23(11):611-8. PubMed ID: 24108193
[TBL] [Abstract][Full Text] [Related]
5. Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation.
Cho HJ; On YK; Bang OY; Kim JW; Huh W; Ko JW; Kim JS; Lee SY
Clin Ther; 2011 Oct; 33(10):1371-80. PubMed ID: 21981797
[TBL] [Abstract][Full Text] [Related]
6. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.
Namazi S; Azarpira N; Hendijani F; Khorshid MB; Vessal G; Mehdipour AR
Clin Ther; 2010 Jun; 32(6):1050-60. PubMed ID: 20637959
[TBL] [Abstract][Full Text] [Related]
7. Optimization of warfarin dose by population-specific pharmacogenomic algorithm.
Pavani A; Naushad SM; Rupasree Y; Kumar TR; Malempati AR; Pinjala RK; Mishra RC; Kutala VK
Pharmacogenomics J; 2012 Aug; 12(4):306-11. PubMed ID: 21358752
[TBL] [Abstract][Full Text] [Related]
8. Retrospective evidence for clinical validity of expanded genetic model in warfarin dose optimization in a South Indian population.
Pavani A; Naushad SM; Mishra RC; Malempati AR; Pinjala R; Kumar TR; Kutala VK
Pharmacogenomics; 2012 Jun; 13(8):869-78. PubMed ID: 22676192
[TBL] [Abstract][Full Text] [Related]
9. Influence of CYP2C9 and vitamin k oxide reductase complex (VKORC)1 polymorphisms on time to determine the warfarin maintenance dose.
Aomori T; Obayashi K; Fujita Y; Araki T; Nakamura K; Nakamura T; Kurabayashi M; Yamamoto K
Pharmazie; 2011 Mar; 66(3):222-5. PubMed ID: 21553655
[TBL] [Abstract][Full Text] [Related]
10. Frequency of VKORC1 (C1173T) and CYP2C9 genetic polymorphisms in Egyptians and their influence on warfarin maintenance dose: proposal for a new dosing regimen.
El Din MS; Amin DG; Ragab SB; Ashour EE; Mohamed MH; Mohamed AM
Int J Lab Hematol; 2012 Oct; 34(5):517-24. PubMed ID: 22533669
[TBL] [Abstract][Full Text] [Related]
11. Genetic testing for warfarin dosing? Not yet ready for prime time.
Bussey HI; Wittkowsky AK; Hylek EM; Walker MB
Pharmacotherapy; 2008 Feb; 28(2):141-3. PubMed ID: 18225960
[No Abstract] [Full Text] [Related]
12. Failure of pharmacogenetic-based dosing algorithms to identify older patients requiring low daily doses of warfarin.
Schwartz JB; Kane L; Moore K; Wu AH
J Am Med Dir Assoc; 2011 Nov; 12(9):633-8. PubMed ID: 21450231
[TBL] [Abstract][Full Text] [Related]
13. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.
Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R
Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846
[TBL] [Abstract][Full Text] [Related]
14. Validation of warfarin pharmacogenetic algorithms in clinical practice.
Marin-Leblanc M; Perreault S; Bahroun I; Lapointe M; Mongrain I; Provost S; Turgeon J; Talajic M; Brugada R; Phillips M; Tardif JC; Dubé MP
Pharmacogenomics; 2012 Jan; 13(1):21-9. PubMed ID: 22176621
[TBL] [Abstract][Full Text] [Related]
15. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients.
Obayashi K; Nakamura K; Kawana J; Ogata H; Hanada K; Kurabayashi M; Hasegawa A; Yamamoto K; Horiuchi R
Clin Pharmacol Ther; 2006 Aug; 80(2):169-78. PubMed ID: 16890578
[TBL] [Abstract][Full Text] [Related]
16. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.
Kimura R; Miyashita K; Kokubo Y; Akaiwa Y; Otsubo R; Nagatsuka K; Otsuki T; Okayama A; Minematsu K; Naritomi H; Honda S; Tomoike H; Miyata T
Thromb Res; 2007; 120(2):181-6. PubMed ID: 17049586
[TBL] [Abstract][Full Text] [Related]
17. The combined effects of clinical factors and CYP2C9 and VKORC1 gene polymorphisms on initiating warfarin treatment in patients after cardiac valve surgery.
Tatarūnas V; Lesauskaite V; Veikutiene A; Grybauskas P; Jakuska P; Benetis R
J Heart Valve Dis; 2012 Sep; 21(5):628-35. PubMed ID: 23167228
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics of vitamin K antagonists: useful or hype?
Lippi G; Franchini M; Favaloro EJ
Clin Chem Lab Med; 2009; 47(5):503-15. PubMed ID: 19397481
[TBL] [Abstract][Full Text] [Related]
19. Algorithms using clinical and genetic data (CYP2C9, VKORC1) are relevant to predict warfarin dose in patients with different INR targets.
Le Cam-Duchez V; Frétigny M; Cailleux N; Gandelin C; Lévesque H; Borg JY
Thromb Res; 2010 Sep; 126(3):e235-7. PubMed ID: 20569971
[No Abstract] [Full Text] [Related]
20. [Anticoagulation with warfarin].
Schinzel H; Nitschmann S
Internist (Berl); 2009 Aug; 50(8):1026-8. PubMed ID: 19499193
[No Abstract] [Full Text] [Related]
[Next] [New Search]
